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Dear Sir,
Falsely elevated C4-carnitine as expression of glutamate
formiminotransferase deficiency in tandem mass spectrometry
newborn screening
After the first report by Millington et al.,1 the development of
electrospray tandem mass spectrometry (MS/MS) has enabled
in recent years the introduction of expanded newborn screening
programs in many countries.2,3 This has led to an increase in the
capacity to detect rare metabolic disorders during the neonatal
period.
The increase of the only C4-acylcarnitine, as detected by
tandem mass spectrometry in newborn screening, is reported
to be related to short chain acyl-CoA dehydrogenase (SCAD)
deficiency (butyrylcarnitine) or isobutyryl-CoA dehydrogenase
(IBD) deficiency (isobutyrylcarnitine).4
Expanded Newborn Screening Pilot Program using MS/MS
is being conducted in three provinces of Tuscany since January
2001, and, being officially mandated by a legislative action, screens
all babies born in Tuscany since November 2004 (approximately
30 000/year) for selected acylcarnitines and amino acids. We report
on a newborn in which the screening showed an isolated apparent
elevation of C4-acylcarnitine usually associated with SCAD or IBD
deficiency. A careful evaluation of the results and the subsequent
biochemical investigations allowed us to demonstrate that this
alteration was due to accumulation of formiminoglutamate (FIGLU).
Acylcarnitines and amino acids in all dried blood spots from
newborn were analysed as butyl esters with the same methodology
described by la Marca et al.5
An Applied Biosystems-Sciex (Toronto, Canada) API 4000 triple-
quadrupole mass spectrometer equipped with a Turbo V-Spray
source was employed.
MS and MS/MS spectra were collected in continuous flow mode
by connecting the infusion pump directly to the Turbo V-Spray
source. A standard solution of 1 ng/µl of each amino acid and
acylcarnitine in water : acetonitrile (30 : 70) containing 0.05% formic
acid was infused at 5 µl/ min. Measurements on samples were
performed by using a Series 1100 Agilent Technologies (Waldbronn,
Germany) CapPump coupled to an Agilent Micro ALS autosampler,
both fully controlled from the API 4000 data system. Experimental
flow rate was 70 µl/ min using water : acetonitrile (30 : 70) containing
0.05% formic acid. The eluent from the column was directed to the
Turbo V-Spray probe. The acquired data were processed using the
Analyst 1.4.1 proprietary software including the ‘Explore’ option
(for spectral interpretation) and the ChemoView software (for
quantitative information generation).
The child was born from consanguineous Pakistani parents
(first cousins) after five uneventful pregnancy. The family history
was unremarkable: two brothers and two sisters were normal. The
delivery was made by caesarean section because of foetal distress
at the 36th week of gestation. At birth, the APGAR score was
9I and 10V, weight 2700 g, length 49 cm, and head circumference
33 cm. Since the first days of life, the infant presented poor
sucking and brought up milk. Expanded newborn screening for
metabolic diseases by tandem mass spectrometry showed levels
of C4-acylcarnitine mildly increased (using a cutoff value of
the mean C 2SDs). The physical examination at 20 days of life
showed normal cardiac, respiratory and abdominal findings and
no dysmorphic features. Increased tendon reflex and mild axial
hypotonia with hypertonia of legs were present. EEG showed
diffuse paroxystic activity. Abdominal and cerebral ultrasound
investigations as well as brain auditory–evoked potentials (BAEPs)
and visual-evoked potentials (VEPs) were normal. Fundus oculi,
ECG and cardiac ultrasound were normal. Laboratory investigations
revealed normocytic anaemia (Hb 10,9, MCV 80,1 fl). Plasma and
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urine amino acid and urinary organic acid were normal. Folate
plasma level was normal (13 ng/ml; n.v. 3–17). At the age of
5 months, the child showed a mild persistent axial hypotonia and a
mild hypertonia of legs. EEG showed interhemispheric asymmetry
and excess of slow waves during sleep. Development Quotient
(DQ) score (Brunet-Lezine psychometric scale-early childhood) was
0.85. An informed consent for these studies was obtained from the
parents.
Apparent C4-acylcarnitine in dried blood spot collected on
the third day of life for newborn screening was 0.68 µM (normal
0.01–0.63). This abnormal value was confirmed twice on the
same neonatal spot before the first recall. At the recall, apparent
C4-acylcarnitine was 0.8 µM. Urinary organic acid analysis did
not show ethylmalonic acid, methylsuccinic acid, butyrylglycine
or isobutyrylglycine as expected metabolites of SCAD or IBD
deficiency. These negative findings pushed us for a careful
re-evaluation of results provided by the MS/MS analysis. In
acylcarnitine profile, close to the increased signal of 288.2 m/z ion
(C4-acylcarnitine), a very high signal of 287.2 m/z ion was present,
which is usually absent in any other sample (Fig. 1). This ion has
been reported by Pitt et al.6 in a study of urinary metabolites of
inborn errors of metabolism as the butyl-ester of FIGLU acid for
which a transition in MRM 287.2 ! 157 m/z is assigned. The
product ion scan spectrum collected on a FIGLU chemical standard
in our laboratory has confirmed that the 157.1 m/z ion was the most
prominent, but a less intense fragment at 85.0 m/z was also present.
Since the latter is a well-known signature fragment for acylcarnitines,
it enabled us to conclude that in acylcarnitine profile the specific
signal at 287.2 m/z should be assigned to FIGLU. Moreover, since the
precursor ion scan of 85.0 m/z ion on the FIGLU chemical standard
showed that the 287.2 m/z quasi-molecular ion was accompanied
by the 288.2 m/z ion (16.8% of 287.2 ion, sensitivity-wise), the latter
rationalised as the first 13C isotopomer.
FIGLU levels subsequently measured with MRM scan function
for the m/z 287.2 ! 157.1 transition (specifically suggested for
FIGLU quantitation) on patient’s blood spot ranged from 5.6–7.1 µM
(normal value 0.01–1.52 from 1000 healthy newborns). Plasma and
urine FIGLU levels are reported in Table 1.
The high levels of FIGLU were also confirmed by the lev-
els found in urine. High FIGLU concentration could be due to
glutamate formiminotransferase deficiency, an autosomal reces-
sive disorder of folate metabolism. The enzyme involved in this
metabolic defect is a bifunctional protein that contains the activ-
ities of glutamate formiminotransferase and formimino-H4folate
cyclodeaminase. This enzyme permits the transfer of formimino
group, coming from the catabolism of histidine, to tetrahydrofo-
late followed by the formation of 5,10-methenyl-H4folate and with
the release of ammonia group.7 Patients affected by glutamate
formiminotransferase deficiency show two distinct phenotypes,
severe and mild. Clinical manifestations of the severe phenotype
include mental retardation, failure to thrive, vomiting,8 cortical atro-
phy, megaloblastic anaemia and hypersegmentation of neutrophils,
while biochemical findings show elevated levels of FIGLU in the
urine and in plasma especially after histidine loading, normal or
high serum folate. Hyperhistidinemia can be also present. In the
mild phenotype, mental retardation is not present, but sometimes
mild developmental delay, no haematological abnormalities, mas-
sive excretion of FIGLU in the urine without histidine loading and
normal serum folate are manifest.8–11 Megaloblastic anaemia is not
always a constant feature.6 Some subjects are asymptomatic and
it is not clear if the above reported symptoms are due to bias of
ascertainment.12
In our patient, the main biochemical findings have been the high
levels of FIGLU in blood or plasma and the massive excretion in urine
without histidine loading. Serum folate and histidine levels were
normal; megaloblastic anaemia was absent. The clinical findings at
the age of 5 months showed only mild psychomotor development
delay (DQ 0.85) and few EEG alterations. For the described patient,
biochemical and clinical data allowed us to suspect the mild form of
glutamate formiminotransferase deficiency.
The expanded newborn screening by tandem mass spec-
trometry in Tuscany has brought about the identification of
a defect not included in our program of newborn screening.
This defect could have poor clinical significance but can be an
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Figure 1. Acylcarnitine profile of affected newborn vs control. In the affected patient, besides the expected 288.2 m/z ion (assigned
to the butylated C4-acylcarnitine), there was a very intense signal at mass 287.2 m/z, which is usually not expected and not related
in any way to the above-mentioned C4-acylcarnitine butyl-ester.
Table 1. FIGLU and C4-acylcarnitine levels on patient’s blood, plasma and urine
Age at sampling
C4-acylcarnitine in
dried blood
spot (µm/l)
C4-acylcarnitine
in plasma (µm/l)
FIGLU in dried
blood spot (µm/l)
FIGLU in
plasma (µm/l)
FIGLU in
urine (µm/mol creat)
3 days 0.68 – 3.66 – –
11 days 0.8 – 5.66 – –
17 days 0.97 – 7.1 – –
19 days – 2.00 – 14.75 399
26 days – 1.78 – 6.95 –
30 days – 1.4 – 9.01 301
2 months – 1.1 – 13.5 –
3 months – 0.88 – 3.73 –
5 months – 1.23 – 3.4 193.5
Normal values 0.01–0.63 0.12–0.44 0.01–1.52 0.21–1.57 0.9–9.3
example of misinterpretation in newborn screening by tandem mass
spectrometry. A false interpretation of metabolic alterations with
unknown or poor clinical significance could create stress in parents
and an increase of professional work in care.13
In conclusion, before investigating for SCAD or IBD deficiency,
it is important to exclude from the acylcarnitine profile the presence
of signal of 287.2 m/z ion near the 288.2 m/z ion (C4-acylcarnitine),
whenever the latter shows an abnormal intensity.
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